JBC Connect with Cosmo for Collagen Detection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.R600038200 on February 28, 2007

J. Biol. Chem., Vol. 282, Issue 16, 11613-11617, April 20, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/16/11613    most recent
R600038200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugimoto, Y.
Right arrow Articles by Narumiya, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugimoto, Y.
Right arrow Articles by Narumiya, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Minireview

Prostaglandin E Receptors*

Yukihiko Sugimoto{ddagger} and Shuh Narumiya§1

From the {ddagger}Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences and the §Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606-8501, Japan


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 Biochemical Properties of PGE...
 Physiological Functions of EP...
 Concluding Remarks
 REFERENCES
 
Prostaglandin (PG) E2 exerts its actions by acting on a group of G-protein-coupled receptors (GPCRs). There are four GPCRs responding to PGE2 designated subtypes EP1, EP2, EP3, and EP4 and multiple splicing isoforms of the subtype EP3. The EP subtypes exhibit differences in signal transduction, tissue localization, and regulation of expression. This molecular and biochemical heterogeneity of PGE receptors leads to PGE2 being the most versatile prostanoid. Studies on knock-out mice deficient in each EP subtype have defined PGE2 actions mediated by each subtype and identified the role each EP subtype plays in various physiological and pathophysiological responses. Here we review recent advances in PGE receptor research.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
Biochemical Properties of PGE...
 Physiological Functions of EP...
 Concluding Remarks
 REFERENCES
 
Prostanoids including various prostaglandins (PGs)2 and thromboxanes (TXs) are cyclooxygenase (COX) metabolites of C20-unsaturated fatty acids such as arachidonic acid. These substances are synthesized in response to various stimuli in a variety of cells, released immediately after synthesis, and act in the vicinity of their synthesis to maintain local homeostasis (1). Among prostanoids, the E type PGs, particularly PGE2 derived from arachidonic acid, is most widely produced in the body, most widely found in animal species, and exhibits the most versatile actions. Receptors mediating prostanoid actions were characterized first by pharmacological analysis, which indicated the presence of one receptor each, named DP, FP, IP, and TP, for PGs of the D, F, and I types and TXA, respectively, and four different receptors designated EP1, EP2, EP3, and EP4 for the E type PGs (reviewed in Refs. 2 and 3). Molecular identification of these receptors was achieved by their cDNA cloning, which revealed that the prostanoid receptors are G-protein-coupled receptors (GPCRs) and that there is indeed a family of eight GPCRs that correspond to the pharmacologically defined receptors. In addition, a recent study revealed the presence of the ninth prostanoid receptor that belongs not to the prostanoid receptor family described above but to the chemoattractant receptor family (4). This receptor called CRTH2 or DP2 is expressed in Th2 cells and eosinophils and mediates some of the PGD2 actions on these cells such as chemotaxis. cDNA cloning also revealed the presence of several splicing variants for EP3. Thus, there are four GPCRs designated subtypes EP1, EP2, EP3, and EP4 and EP3 variants mediating PGE2 actions. Subsequent analysis has revealed distinct biochemical properties and tissue and cellular localization of each EP subtype. The cloned EP subtypes have also been used in the development of compounds specific to each subtype.


   Biochemical Properties of PGE Receptor Subtypes and Isoforms
TOP
 ABSTRACT
 INTRODUCTION
 Biochemical Properties of PGE...
Physiological Functions of EP...
 Concluding Remarks
 REFERENCES
 
Molecular Structures—Fig. 1 shows an alignment of the primary amino acid sequences of the mouse EP1, EP2, and EP4 and three isoforms of mouse EP3 receptors. The mouse EP1, EP2, EP3 (EP3{alpha}), and EP4 receptors consist of 405, 362, 366, and 513 amino acids, respectively. EP4 has the longest intracellular C terminus and a relatively long intracellular third loop. The EP1 receptor also has a long third loop, whereas the EP2 and EP3 receptors have a more compact structure. A remarkable feature distinguishing the EP3 receptor from the other EP receptors is the existence of multiple variants generated by alternative splicing of the C-terminal tail. In mouse, alternative splicing creates three EP3 splice isoforms, {alpha}, beta, and {gamma}, containing C-terminal tails of 30, 26, and 29 amino acids that do not share any structural motifs or hydrophobic features (5, 6). These isoforms show similar ligand binding properties but have different signal transduction properties as described below. Multiple splice isoforms for EP3 also exist in other species including rat, rabbit, bovine, and human (3). Although all of the four EP subtypes respond to PGE2, the amino acid identity among the EPs is limited; the identity of EP1 to EP2, EP3, and EP4 is 30, 33, and 28%, respectively. The amino acid identity is only 31% even between the two EPs (EP2 and EP4) that couple to the activation of adenylate cyclase. The EP2 receptor is more homologous to IP (40%) and DP (44%), the other two adenylate cyclase-stimulatory prostanoid receptors, than any other EPs, and the EP1 receptor is more homologous to FP (35%) and TP (34%) than other EPs. This limited homology among EPs probably reflects the phylogenetic relationship among the prostanoid receptors (7).

Ligand Binding Properties—The EP subtypes bind most potently to PGE2 with Kd values in the range of 1–40 nM. Iloprost, an IP agonist, also binds to EP1 and EP3 with Ki values of about 20 nM. The PGE analogs that have been used in conventional studies are not specific for any given EP subtype except butaprost, which is specific for EP2. Several compounds highly selective for each EP subtype have been developed using cultured cell lines stably expressing each subtype. Examples are shown in Fig. 2 (8–11).

Signal Transduction Properties—Signal transduction pathways of EP subtypes have been studied by examining agonist-induced changes in second messengers such as cAMP, Ca2+, and inositol phosphates and agonist-induced changes in activities of downstream kinases. The EP1 receptor mediates a PGE2-induced elevation of the free Ca2+ concentration in Chinese hamster ovary cells. This increase is dependent on extracellular Ca2+ and occurs without a detectable phosphatidylinositide response (12), suggesting that EP1 regulates Ca2+ channel gating via an unidentified G protein. It was reported that EP1 expressed in Xenopus oocytes can couple to TRP5, a candidate for the receptor-activated Ca2+ channel, and this coupling is inhibited by an antisense oligonucleotide for Gq/G11 but not by one for Gi1 (13). The EP2 and EP4 receptors couple to Gs and mediate increases in cAMP concentrations. The major signaling pathway of the EP3 receptor is inhibition of adenylate cyclase via Gi. It should be noted, however, that the EP receptors do not couple exclusively to the pathways described but often to more than one G protein and signal transduction pathway (Table 1). Of interest in this respect is the presence of two EPs, EP2 and EP4, that are coupled to increases in cAMP. They apparently function redundantly in some processes. For example, both EP2 and EP4 mediate induction of RANKL through cAMP by PGE2 in osteoclastogenesis, although the extent of the contribution by each receptor may be different (14, 15). On the other hand, there are processes in which EP2 and EP4 play distinct roles. Some of these may be because of selective expression of either of them in relevant cells such as the action of EP2 during cumulus expansion in ovulation and fertilization (16) and that of EP4 in closure of the ductus arteriosus (17). However, only EP4 regulates migration of dendritic cells in the mouse although both EP2 and EP4 are expressed in these cells (18). This EP4-selective action may be related to the fact that EP4 but not EP2 couples to phosphatidylinositol 3-kinase, probably via Gi, in addition to activation of adenylate cyclase (19, 20). It is interesting in this respect that EP4 is also implicated in cell migration during tumor invasion (21) for ductus arteriosus closure (22) and for zebrafish gastrulation (23). As described, the EP3 receptor consists of multiple isoforms generated by alternative splicing of the C-terminal tail. Functional differences among these splice variants have been reported, including coupling to different signal transduction pathways (Table 1) (24), different sensitivities to agonist-induced desensitization (25), different extents of constitutive activity (26), different intracellular trafficking patterns (27), and different agonist-induced internalization patterns (28).


Figure 1
View larger version (70K):
[in this window]
[in a new window]

  		FIGURE 1.
Amino acid sequence alignments of the mouse EP2, EP4, EP1, and three isoforms of EP3 receptors. Amino acid identity (three or four out of four subtypes) is indicated by shading; predicted transmembrane domains are shown by overlining, and gaps are indicated by dashes.

 


Figure 2
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 2.
Structures of prostaglandin E2 and EP-selective agonists and antagonists. The Ki values (nM) of the compounds obtained by competition-binding isotherms to displace [3H]PGE2 binding to the EP1, EP2, EP3, and EP4 receptors are shown in parentheses (8–11). Additional information about the structures and binding affinities of other synthetic compounds for EPs is available at the IUPHAR Receptor Data base site (www.iuphar-db.org/GPCR/index.html).

 


View this table:
[in this window]
[in a new window]

  		TABLE 1
Signal transduction properties of EP receptor subtypes and EP3 isoforms

Data obtained from mouse EP subtypes are summarized, and representative signal transduction pathways for each receptor are shown. PI3K, phosphatidylinositol 3-kinase; {uparrow}, increase; {downarrow}, decrease.

 
Tissue Distribution and Cellular Localization—Northern blot analysis and in situ hybridization have provided detailed information about EP receptor distribution and have shown that each receptor is specifically distributed in the body and that the expression levels are variable among tissues. The tissue distribution of the mouse EP subtypes assessed by Northern blot analyses is presented in Fig. 3A (29–32). Among the four EPs, EP3 and EP4 receptors are the most widely distributed with their mRNAs being expressed in almost all mouse tissues examined. In contrast, the distribution of EP1 mRNA is restricted to several organs, such as the kidney, lung, and stomach, and EP2 is the least abundant of the EP receptors. Within tissues, each EP subtype shows a distinct cellular localization. For example, in the kidney, EP3 is expressed in the tubular epithelium, the thick ascending limb, and the cortical collecting ducts in the outer medulla, EP1 in the papillary collecting ducts, and EP4 in the glomerulus (33) (Fig. 3B). This distribution pattern appears to correlate with the PGE2-mediated regulation of ion transport, water reabsorption, and glomerular filtration, respectively. A similar distribution of EPs in the kidney has been reported in the rabbit and human (34, 35). These analyses did not detect signals for EP2 mRNA in the kidney.


Figure 3
View larger version (86K):
[in this window]
[in a new window]

  		FIGURE 3.
A, tissue distribution of EP subtypes. Poly(A)+ RNA isolated from the indicated tissues (5 µg for EP1 and EP2; 10 µg for EP3 and EP4) was applied in each lane. Hybridization was carried out using the antisense RNA probes (EP1 and EP2) or cDNA fragment probes (EP3 and EP4) (29–32). B, localization of EP subtypes in mouse kidney. In situ hybridization signals for EP1, EP3, and EP4 in renal sections are presented in a dark-field manner (33). Bar = 1 mm.

 
Regulation of Expression—Expression of EP genes is regulated by various physiological and pathophysiological stimuli. In peritoneal resident macrophages (36) and a macrophage cell line, J774.1 (37), EP4 is expressed under basal conditions. The addition of lipopolysaccharide (LPS) induces EP2 expression markedly in both types of cells but enhances the EP4 expression only slightly in J774.1 cells and suppresses the expression of EP4 in the resident macrophages (36). Macrophages produce a large amount of PGE2 in response to LPS, and suppression of the EP4 expression in the resident macrophages was prevented by treatment with indomethacin and was mimicked by the addition of dibutyryl cAMP or PGE2 but not butaprost, suggesting that EP4 expression is regulated through a negative feedback loop. The presence of EP2 and EP4 and augmentation of their expression by LPS stimulation were also seen in the RAW 264.7 murine macrophage-like cell line (38). Quantitative reverse transcription-PCR analysis indicated a 3-fold increase in EP4 mRNA 2.5 h after LPS stimulation. In thioglycolate-elicited macrophages, macrophage engagement with extra-cellular matrix induces expression of both EP2 and EP4 and COX-2 in a MAPKerk1/2-dependent manner (39).

In female reproductive organs such as the ovary and uterus, hormonal exposure induces expression of the EP subtypes in specific cell types. In the ovary, the EP4 expression is found in oocytes in preantral follicles. Upon gonadotropin stimulation, this expression disappears, and EP4 is expressed first in both granulosa cells and cumulus cells and then only in granulosa cells in preovulatory follicles. EP2 expression is found in both granulosa cells and cumulus cells in preantral follicles. This expression increases upon gonadotropin stimulation and becomes confined to the cumulus cells just before ovulation. Interestingly, COX-2 expression changes in a similar pattern to EP2 upon gonadotropin stimulation in cumulus and mural granulosa cells (40). In the uterus, when mice are primed with gonadotropins and undergo pseudopregnancy, EP2 is transiently expressed on day 5 in luminal epithelial cells. EP4 expression is limited to luminal epithelial cells on day 0, sharply increases on day 3, and is then found in endometrial stromal cells as well as glandular epithelium. EP3 expression is found in longitudinal muscle layer before stimulation. After stimulation, this expression disappears and EP3 is expressed in circular smooth muscles with a further increase on days 3 and 5 (41).

Promoter analysis has been done for EP2 and EP4. Several consensus sequences relevant to inflammatory stimuli such as those for NF-IL6, NF{kappa}B, and AP2 are found, and several regions responsive to progesterone have been characterized in the promoter region of the EP2 gene (42). The promoter region of the EP4 gene contains several putative cis-acting elements such as sites for AP1, AP2, Sp1, NF{kappa}B, MyoD, and NF-IL6 as well as a putative glucocorticoid response element. Functional analysis detected an LPS/serum-responsive region between –554 and –116 bp (38).


   Physiological Functions of EP Subtypes
TOP
 ABSTRACT
 INTRODUCTION
 Biochemical Properties of PGE...
 Physiological Functions of EP...
Concluding Remarks
 REFERENCES
 
Mice deficient in each EP subtype individually have been generated, and studies using these knock-out mice and subtype-specific EP agonists/antagonists have identified EP subtypes mediating various PGE2 actions (Table 2). EP subtypes mediate many processes known to be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs). For example, the EP3 receptor mediates generation of pyrogenic fever (54), and EP1 and EP3 signals converge at the paraventricular nucleus of the hypothalamus and mediate neuroendocrine stress response by facilitating release of corticotropin-releasing hormone (43). EP2 facilitates ovulation and fertilization by inducing expansion of the cumulus, thus clarifying the mechanism for the inhibitory effect of NSAIDs on ovulation (16). Other studies have revealed that different EP subtypes as well as the IP receptor function in hyperalgesia both at the periphery and in the CNS. For example, the acetic acid writhing test revealed the involvement of both IP and EP3 in hyperalgesia (57, 61). Pain sensation that is induced by pH and heat and mediated by the capsaicin receptor TRPV1 is augmented by PGE2 and PGI2 acting on EP1 and IP, respectively (46). Furthermore, in the spinal cord, PGE2 acting on EP2 in glycinergic neurons abolishes the glycine-induced tonic inhibition of pain neuron in the dorsal horn and facilitates the propagation of nociceptive signals through the spinal cord to higher areas of the CNS (48).


View this table:
[in this window]
[in a new window]

  		TABLE 2
Physiological function of EP receptor subtypes

Physiological and pathophysiological actions of EP receptor subtypes based on the studies using each receptor-deficient mice are shown.

 
Prostanoids, particularly PGE2, have been thought to play a major role in acute inflammation by acting on the peripheral circulation and inducing hyperemia and swelling. One of the lessons learned from the knock-out mouse studies, however, is that prostanoids including PGE2 exert both pro-inflammatory and anti-inflammatory responses, and these actions are often produced through regulation of gene expression in relevant tissues. For example, consistent with the anti-inflammatory and anti-arthritic effect of NSAIDs, EP2 and EP4 (and IP) redundantly mediate development of collagen-induced arthritis (49). Intriguingly, however, the pro-inflammatory actions of these prostanoid receptors are elicited mainly by induction of arthritis-associated genes in the joint. As for inflammatory swelling, studies using the carrageenin-induced paw edema model revealed involvement of IP (61), and those using carrageenin-induced pleurisy revealed participation of EP2, EP3, and IP in inflammatory exudation (62). Anti-inflammatory actions of prostanoids are seen typically in allergic or immune inflammation and are usually balanced by pro-inflammatory actions of other prostanoids. This may explain why NSAIDs are without effects on allergy and immune responses. Examples are the antagonism between the PGD2-DP (63) and the PGE2-EP3 (55) pathways in elicitation of allergic asthma. DP and EP3 are both present in the airway epithelium, and activation of the latter suppresses expression of a series of allergy-related genes and progression of allergic inflammation. Knock-out mice studies have also revealed that prostanoids work at multiple steps in hapten-induced immune responses. Interestingly, most of these actions are found in the immunization and not in the elicitation process. The PGD2-DP pathway suppresses (64) and the PGE2-EP4 pathway facilitates (18) mobilization, migration, and maturation of Langerhans cells in the skin, and the TXA2-TP pathway negatively modulates interaction between activated Langerhans cells and naïve T-cells, thereby suppressing T-cell proliferation and differentiation (65). PGE2 together with other prostanoids can thus modulate various steps of inflammation in a context-dependent manner and coordinate the whole process in both pro-inflammatory and anti-inflammatory directions.


   Concluding Remarks
TOP
 ABSTRACT
 INTRODUCTION
 Biochemical Properties of PGE...
 Physiological Functions of EP...
 Concluding Remarks
REFERENCES
 
The mechanisms whereby PGE2 exerts its pleiotropic effects, once a mystery in physiology, have been clarified through the biochemical identification and cDNA cloning of the four EP subtype receptors. Furthermore, development of highly selective agonists and antagonists to each EP subtype and information obtained by studies on mice deficient in each EP receptor now provide opportunities to apply our knowledge to manipulate various PGE2-mediated pathological processes.


   FOOTNOTES
 
* This minireview will be reprinted in the 2007 Minireview Compendium, which will be available in January, 2008. Work in our laboratories was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports Science and Technology of Japan and from the Ministry of Health and Labor of Japan. Back

1 To whom correspondence should be addressed. E-mail: snaru{at}mfour.med.kyoto-u.ac.jp.

2 The abbreviations used are: PG, prostaglandin; CNS, central nervous system; COX, cyclooxygenase; GPCR, G-protein-coupled receptor; LPS, lipopolysaccharide; NSAID, non-steroidal anti-inflammatory drug; TX, thromboxane. Back


   ACKNOWLEDGMENTS
 
We thank all members of our departments and all collaborators on prostanoid receptors.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 Biochemical Properties of PGE...
 Physiological Functions of EP...
 Concluding Remarks
 REFERENCES
 

  1. Smith, W. L., and Langenbach, R. (2001) J. Clin. Invest. 107, 1491–1495[Medline] [Order article via Infotrieve]
  2. Coleman, R. A., Smith, W. L., and Narumiya, S. (1994) Pharmacol. Rev. 46, 205–229[Medline] [Order article via Infotrieve]
  3. Narumiya, S., Sugimoto, Y., and Ushikubi, F. (1999) Physiol. Rev. 79, 1193–1226[Abstract/Free Full Text]
  4. Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., and Nagata, K. (2001) J. Exp. Med. 193, 255–261[Abstract/Free Full Text]
  5. Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712–2718[Abstract/Free Full Text]
  6. Irie, A., Sugimoto, Y., Namba, A., Harazono, A., Honda, A., Watabe, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) Eur. J. Biochem. 217, 313–318[Medline] [Order article via Infotrieve]
  7. Toh, H., Ichikawa, A., and Narumiya, S. (1995) FEBS Lett. 361, 17–21[CrossRef][Medline] [Order article via Infotrieve]
  8. Kiriyama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y., and Narumiya, S. (1997) Br. J. Pharmacol. 122, 217–224[CrossRef][Medline] [Order article via Infotrieve]
  9. Suzawa, T., Miyaura, C., Inada, M., Maruyama, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S., and Suda, T. (2000) Endocrinology 141, 1554–1559[Abstract/Free Full Text]
  10. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A., and Narumiya, S. (2002) J. Clin. Invest. 109, 883–893[CrossRef][Medline] [Order article via Infotrieve]
  11. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., Murata, T., Yoshimura, H., Narumiya, S., and Majima, M. (2003) J. Exp. Med. 197, 221–232[Abstract/Free Full Text]
  12. Katoh, H., Watabe, A., Sugimoto, Y., Ichikawa, A., and Negishi, M. (1995) Biochim. Biophys. Acta 1244, 41–48[Medline] [Order article via Infotrieve]
  13. Tabata, H., Tanaka, S., Sugimoto, Y., Kanki, H., Kaneko, S., and Ichikawa, A. (2002) Biochem. Biophys. Res. Commun. 298, 398–402[CrossRef][Medline] [Order article via Infotrieve]
  14. Li, X., Okada, Y., Pilbeam, C. C., Lorenzo, J. A., Kennedy, C. R., Breyer, R. M., and Raisz, L. G. (2000) Endocrinology 141, 2054–2061[Abstract/Free Full Text]
  15. Ono, K., Akatsu, T., Kugai, N., Pilbeam, C. C., and Raisz, L. G. (2003) Bone 33, 798–804[Medline] [Order article via Infotrieve]
  16. Hizaki, H., Segi, E., Sugimoto, Y., Hirose, M., Saji, T., Ushikubi, F., Matsuoka, T., Noda, Y., Tanaka, T., Yoshida, N., Narumiya, S., and Ichikawa, A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10501–10506[Abstract/Free Full Text]
  17. Segi, E., Sugimoto, Y., Yamasaki, A., Aze, Y., Oida, H., Nishimura, T., Murata, T., Matsuoka, T., Ushikubi, F., Hirose, M., Tanaka, T., Yoshida, N., Narumiya, S., and Ichikawa, A. (1998) Biochem. Biophys. Res. Commun. 246, 7–12[CrossRef][Medline] [Order article via Infotrieve]
  18. Kabashima, K., Sakata, D., Nagamachi, M., Miyachi, Y., Inaba, K., and Narumiya, S. (2003) Nat. Med. 9, 744–749[CrossRef][Medline] [Order article via Infotrieve]
  19. Fujino, H., Xu, W., and Regan, J. W. (2003) J. Biol. Chem. 278, 12151–12156[Abstract/Free Full Text]
  20. Fujino, H., and Regan, J. W. (2006) Mol. Pharmacol. 69, 5–10[Abstract/Free Full Text]
  21. Timoshenko, A.V., Xu, G., Chakrabarti, S., Lala, P.K., and Chakraborty, C. (2003) Exp. Cell Res. 289, 265–274[CrossRef][Medline] [Order article via Infotrieve]
  22. Yokoyama, U., Minamisawa, S., Hong, Q., Ghatak, S., Akaike, T., Segi-Nishida, E., Iwasaki, S., Iwamoto, M., Misra, S., Tamura, K., Hori, H., Yokota, S., Toole, B. P., Sugimoto, Y., and Ishikawa, Y. (2006) J. Clin. Invest. 116, 3026–3034[CrossRef][Medline] [Order article via Infotrieve]
  23. Cha, Y. I., Kim, S. H., Sepich, D., Buchanan, F. G., Solnica-Krezel, L., and DuBois, R. N. (2006) Genes Dev. 20, 77–86[Abstract/Free Full Text]
  24. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., and Narumiya, S. (1993) Nature 365, 166–170[CrossRef][Medline] [Order article via Infotrieve]
  25. Negishi, M., Sugimoto, Y., Irie, A., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 9517–9521[Abstract/Free Full Text]
  26. Hasegawa, H., Negishi, M., and Ichikawa, A. (1996) J. Biol. Chem. 271, 1857–1860[Abstract/Free Full Text]
  27. Hasegawa, H., Katoh, H., Yamaguchi, Y., Nakamura, K., Futakawa, S., and Negishi, M. (2000) FEBS Lett. 473, 76–80[CrossRef][Medline] [Order article via Infotrieve]
  28. Bilson, H. A., Mitchell, D. L., and Ashby, B. (2004) FEBS Lett. 572, 271–275[CrossRef][Medline] [Order article via Infotrieve]
  29. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and Narumiya, S. (1992) J. Biol. Chem. 267, 6463–6466[Abstract/Free Full Text]
  30. Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 7759–7762[Abstract/Free Full Text]
  31. Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 20175–20178[Abstract/Free Full Text]
  32. Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M., Narumiya, S., and Ichikawa, A. (1995) FEBS Lett. 372, 151–156[CrossRef][Medline] [Order article via Infotrieve]
  33. Sugimoto, Y., Namba, T., Shigemoto, R., Negishi, M., Ichikawa, A., and Narumiya, S. (1994) Am. J. Physiol. 266, F823–F828[Medline] [Order article via Infotrieve]
  34. Breyer, M. D., Jacobson, H. R., Davis, L., and Breyer, R. M. (1993) Kidney Int. 44, 1372–1378[Medline] [Order article via Infotrieve]
  35. Breyer, M. D., Davis, L., Jacobson, H. R., and Breyer, R. M. (1996) Am. J. Physiol. 270, F912–F918[Medline] [Order article via Infotrieve]
  36. Ikegami, R., Sugimoto, Y., Segi, E., Katsuyama, M., Karahashi, H., Amano, F., Maruyama, T., Yamane, H., Tsuchiya, S., and Ichikawa, A. (2001) J. Immunol. 166, 4689–4696[Abstract/Free Full Text]
  37. Katsuyama, M., Ikegami, R., Karahashi, H., Amano, F., Sugimoto, Y., and Ichikawa, A. (1998) Biochem. Biophys. Res. Commun. 251, 727–731[CrossRef][Medline] [Order article via Infotrieve]
  38. Arakawa, T., Laneuville, O., Miller, C. A., Lakkides, K. M., Wingerd, B. A., DeWitt, D. L., and Smith, W. L. (1996) J. Biol. Chem. 271, 29569–29575[Abstract/Free Full Text]
  39. Pavlovic, S., Du, B., Sakamoto, K., Khan, K. M., Natarajan, C., Breyer, R. M., Dannenberg, A. J., and Falcone, D. J. (2006) J. Biol. Chem. 281, 3321–3328[Abstract/Free Full Text]
  40. Segi, E., Haraguchi, K., Sugimoto, Y., Tsuji, M., Tsunekawa, H., Tamba, S., Tsuboi, K., Tanaka, S., and Ichikawa, A. (2003) Biol. Reprod. 68, 804–811[Abstract/Free Full Text]
  41. Katsuyama, M., Sugimoto, Y., Morimoto, K., Hasumoto, K., Fukumoto, M., Negishi, M., and Ichikawa, A. (1997) Endocrinology 138, 344–350[Abstract/Free Full Text]
  42. Tsuchiya, S., Tanaka, S., Sugimoto, Y., Katsuyama, M., Ikegami, R., and Ichikawa, A. (2003) Genes Cells 8, 747–758[Abstract]
  43. Matsuoka, Y., Furuyashiki, T., Bito, H., Ushikubi, F., Tanaka, Y., Kobayashi, T., Muro, S., Satoh, N., Kayahara, T., Higashi, M., Mizoguchi, A., Shichi, H., Fukuda, Y., Nakao, K., and Narumiya, S. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4132–4137[Abstract/Free Full Text]
  44. Matsuoka, Y., Furuyashiki, T., Yamada, K., Nagai, T., Bito, H., Tanaka, Y., Kitaoka, S., Ushikubi, F., Nabeshima, T., and Narumiya, S. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 16066–16071[Abstract/Free Full Text]
  45. Mutoh, M., Watanabe, K., Kitamura, T., Shoji, Y., Takahashi, M., Kawamori, T., Tani, K., Kobayashi, M., Maruyama, T., Kobayashi, K., Ohuchida, S., Sugimoto, Y., Narumiya, S., Sugimura, T., and Wakabayashi, K. (2002) Cancer Res. 62, 28–32[Abstract/Free Full Text]
  46. Moriyama, T., Higashi, T., Togashi, K., Iida, T., Segi, E., Sugimoto, Y., Tominaga, T., Narumiya, S., and Tominaga, M. (2005) Mol. Pain 1, 3[CrossRef][Medline] [Order article via Infotrieve]
  47. Sonoshita, M., Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., Oshima, M., and Taketo, M. M. (2001) Nat. Med. 7, 1048–1051[CrossRef][Medline] [Order article via Infotrieve]
  48. Reinold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., Pahl, A., Brune, K., Narumiya, S., Muller, U., and Zeilhofer, H. U. (2005) J. Clin. Invest. 115, 673–679[CrossRef][Medline] [Order article via Infotrieve]
  49. Honda, T., Segi-Nishida, E., Miyachi, Y., and Narumiya, S. (2006) J. Exp. Med. 203, 325–335[Abstract/Free Full Text]
  50. Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R. L., Morrow, J. D., Shyr, Y., Boothby, M., Joyce, S., Carbone, D. P., and Breyer, R. M. (2003) J. Clin. Invest. 111, 727–735[CrossRef][Medline] [Order article via Infotrieve]
  51. Sugimoto, Y., Fukada, Y., Mori, D., Tanaka, S., Yamane, H., Okuno, Y., Deai, K., Tsuchiya, S., Tsujimoto, G., and Ichikawa, A. (2005) J. Immunol. 175, 2606–2612[Abstract/Free Full Text]
  52. Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R. M., Montine, T. J., and Andreasson, K. (2005) J. Neurosci. 25, 10180–10187[Abstract/Free Full Text]
  53. Chang, S. H., Ai, Y., Breyer, R. M., Lane, T. F., and Hla, T. (2005) Cancer Res. 65, 4496–4499[Abstract/Free Full Text]
  54. Ushikubi, F., Segi, E., Sugimoto, Y., Murata, T., Matsuoka, T., Kobayashi, T., Hizaki, H., Tuboi, K., Katsuyama, M., Ichikawa, A., Tanaka, T., Yoshida, N., and Narumiya, S. (1998) Nature 395, 281–284[CrossRef][Medline] [Order article via Infotrieve]
  55. Kunikata, T., Yamane, H., Segi, E., Matsuoka, T., Sugimoto, Y., Tanaka, S., Tanaka, H., Nagai, H., Ichikawa, A., and Narumiya, S. (2005) Nat. Immunol. 6, 524–531[CrossRef][Medline] [Order article via Infotrieve]
  56. Takeuchi, K., Ukawa, H., Kato, S., Furukawa, O., Araki, H., Sugimoto, Y., Ichikawa, A., Ushikubi, F., and Narumiya, S. (1999) Gastroenterology 117, 1128–1135[CrossRef][Medline] [Order article via Infotrieve]
  57. Ueno, A., Matsumoto, H., Naraba, H., Ikeda, Y., Ushikubi, F., Matsuoka, T., Narumiya, S., Sugimoto, Y., Ichikawa, A., and Oh-ishi, S. (2001) Biochem. Pharmacol. 62, 157–160[CrossRef][Medline] [Order article via Infotrieve]
  58. Minami, T., Matsumura, S., Mabuchi, T., Kobayashi, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S., and Ito, S. (2003) Neuropharmacology 45, 96–105[CrossRef][Medline] [Order article via Infotrieve]
  59. Takasaki, I., Nojima, H., Shiraki, K., Sugimoto, Y., Ichikawa, A., Ushikubi, F., Narumiya, S., and Kuraishi, Y. (2005) Neuropharmacology 49, 283–292[Medline] [Order article via Infotrieve]
  60. Yoshida, K., Oida, H., Kobayashi, T., Maruyama, T., Tanaka, M., Katayama, T., Yamaguchi, K., Segi, E., Tsuboyama, T., Matsushita, M., Ito, K., Ito, Y., Sugimoto, Y., Ushikubi, F., Ohuchida, S., Kondo, K., Nakamura, T., and Narumiya, S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4580–4585[Abstract/Free Full Text]
  61. Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., and Narumiya, S. (1997) Nature 388, 678–682[CrossRef][Medline] [Order article via Infotrieve]
  62. Yuhki, K., Ueno, A., Naraba, H., Kojima, F., Ushikubi, F., Narumiya, S., and Oh-ishi, S. (2004) J. Pharmacol. Exp. Ther. 311, 1218–1224[Abstract/Free Full Text]
  63. Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto, Y., Kobayashi, T., Ushikubi, F., Aze, Y., Eguchi, N., Urade, Y., Yoshida, N., Kimura, K., Mizoguchi, A., Honda, Y., Nagai, H., and Narumiya, S. (2000) Science 287, 2013–2017[Abstract/Free Full Text]
  64. Herve, M., Angeli, V., Pinzar, E., Wintjens, R., Faveeuw, C., Narumiya, S., Capron, A., Urade, Y., Capron, M., Riveau, G., and Trottein, F. (2003) Eur. J. Immunol. 33, 2764–2772[CrossRef][Medline] [Order article via Infotrieve]
  65. Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., Kinashi, T., Tanaka, T., Miyasaka, M., Nagai, H., Ushikubi, F., and Narumiya, S. (2003) Nat. Immunol. 4, 694–701[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Attur, H. E. Al-Mussawir, J. Patel, A. Kitay, M. Dave, G. Palmer, M. H. Pillinger, and S. B. Abramson
Prostaglandin E2 Exerts Catabolic Effects in Osteoarthritis Cartilage: Evidence for Signaling via the EP4 Receptor
J. Immunol., October 1, 2008; 181(7): 5082 - 5088.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Tamba, R. Yodoi, E. Segi-Nishida, A. Ichikawa, S. Narumiya, and Y. Sugimoto
Timely interaction between prostaglandin and chemokine signaling is a prerequisite for successful fertilization
PNAS, September 23, 2008; 105(38): 14539 - 14544.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
H. Shiraishi, H. Yoshida, K. Saeki, Y. Miura, S. Watanabe, T. Ishizaki, M. Hashimoto, G. Takaesu, T. Kobayashi, and A. Yoshimura
Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cells
Int. Immunol., September 1, 2008; 20(9): 1219 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
F. Pierucci-Alves and B. D. Schultz
Bradykinin-Stimulated Cyclooxygenase Activity Stimulates Vas Deferens Epithelial Anion Secretion In Vitro in Swine and Humans
Biol Reprod, September 1, 2008; 79(3): 501 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Togo, O. Holz, X. Liu, H. Sugiura, K. Kamio, X. Wang, S. Kawasaki, Y. Ahn, K. Fredriksson, C. M. Skold, et al.
Lung Fibroblast Repair Functions in Patients with Chronic Obstructive Pulmonary Disease Are Altered by Multiple Mechanisms
Am. J. Respir. Crit. Care Med., August 1, 2008; 178(3): 248 - 260.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
P. Rastogi, A. Rickard, N. Dorokhov, D. J. Klumpp, and J. McHowat
Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1129 - F1135.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Tsuchiya, T. Oka, K. Nakamura, A. Ichikawa, C. B. Saper, and Y. Sugimoto
Prostaglandin E2 Attenuates Preoptic Expression of GABAA Receptors via EP3 Receptors
J. Biol. Chem., April 18, 2008; 283(16): 11064 - 11071.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Minami, K. Shimizu, Y. Okamoto, E. Folco, M.-L. Ilasaca, M. W. Feinberg, M. Aikawa, and P. Libby
Prostaglandin E Receptor Type 4-associated Protein Interacts Directly with NF-{kappa}B1 and Attenuates Macrophage Activation
J. Biol. Chem., April 11, 2008; 283(15): 9692 - 9703.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
A.M. Patwardhan, J. Vela, J. Farugia, K. Vela, and K.M. Hargreaves
Trigeminal Nociceptors Express Prostaglandin Receptors
J. Dent. Res., March 1, 2008; 87(3): 262 - 266.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg
EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE
J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L.-K. Sun, T. Reding, M. Bain, M. Heikenwalder, D. Bimmler, and R. Graf
Prostaglandin E2 modulates TNF-{alpha}-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner
Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1196 - G1204.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
T. G Kennedy, C. Gillio-Meina, and S. H. Phang
Prostaglandins and the initiation of blastocyst implantation and decidualization
Reproduction, November 1, 2007; 134(5): 635 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Wada, C. J. DeLong, Y. H. Hong, C. J. Rieke, I. Song, R. S. Sidhu, C. Yuan, M. Warnock, A. H. Schmaier, C. Yokoyama, et al.
Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products
J. Biol. Chem., August 3, 2007; 282(31): 22254 - 22266.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/16/11613    most recent
R600038200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugimoto, Y.
Right arrow Articles by Narumiya, S.
Right arrow